Mark Schiffman

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria
    Megan A Clarke
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Infect Agent Cancer 6:12. 2011
  2. ncbi A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010
  3. ncbi Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing
    Mark Schiffman
    Human Papillomavirus Research Unit, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Cancer 111:145-53. 2007
  4. ncbi A study of the impact of adding HPV types to cervical cancer screening and triage tests
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:147-50. 2005
  5. ncbi Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, 20892, USA
    Infect Agent Cancer 4:8. 2009
  6. ncbi Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
  7. ncbi Findings to date from the ASCUS-LSIL Triage Study (ALTS)
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:946-9. 2003
  8. ncbi Human papillomavirus: epidemiology and public health
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:930-4. 2003
  9. ncbi Human papillomavirus and cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet 370:890-907. 2007
  10. ncbi The carcinogenicity of human papillomavirus types reflects viral evolution
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MA, USA
    Virology 337:76-84. 2005

Detail Information

Publications133 found, 100 shown here

  1. ncbi A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria
    Megan A Clarke
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Infect Agent Cancer 6:12. 2011
    ..abstract:..
  2. ncbi A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010
    ..Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity...
  3. ncbi Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing
    Mark Schiffman
    Human Papillomavirus Research Unit, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Cancer 111:145-53. 2007
    ..Nevertheless, it is worth describing in broad terms for the readers of Cancer Cytopathology how successful, broad HPV vaccination of adolescent girls may affect cytology and HPV testing...
  4. ncbi A study of the impact of adding HPV types to cervical cancer screening and triage tests
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:147-50. 2005
    ..The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer...
  5. ncbi Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, 20892, USA
    Infect Agent Cancer 4:8. 2009
    ..This article describes for open discussion an approach recently taken by a World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group to re-assess the carcinogenicity of different HPV types...
  6. ncbi Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
    ..The greatest potential for reduction in cervical cancer rates from HPV screening is in low-resource regions that can implement infrequent rounds of low-cost HPV testing and treatment...
  7. ncbi Findings to date from the ASCUS-LSIL Triage Study (ALTS)
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:946-9. 2003
    ..Many additional analyses are underway...
  8. ncbi Human papillomavirus: epidemiology and public health
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:930-4. 2003
    ....
  9. ncbi Human papillomavirus and cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet 370:890-907. 2007
    ..If applied wisely, HPV-related technology can minimise the incidence of cervical cancer, and the morbidity and mortality it causes, even in low-resource settings...
  10. ncbi The carcinogenicity of human papillomavirus types reflects viral evolution
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MA, USA
    Virology 337:76-84. 2005
    ..These results present several clear clues and research directions in our ongoing efforts to understand HPV carcinogenesis...
  11. ncbi Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rm 7066, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Infect Dis 186:1169-72. 2002
    ..001). It appears that the natural history of HPV typically includes periods before and after cytologic abnormality, in which HPV DNA is the more sensitive indicator of infection...
  12. ncbi High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease
    Patti E Gravitt
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Int J Cancer 121:2787-93. 2007
    ..The extent to which these observations can be translated into clinical practice must be rigorously examined in the context of the method of viral load measurement and the type-specific differences observed for incident >/=CIN2...
  13. ncbi Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    J Natl Cancer Inst 102:1794-804. 2010
    ..In a large prospective cohort, we assessed the role of C trachomatis in cervical premalignancy and addressed confounding by HPV...
  14. ncbi A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation
    Patti E Gravitt
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 12:477-84. 2003
    ..The nonrandom distribution of multiple infections by case-control status and the apparent differential effect of viral load by genotype warrant caution when using HC 2 measurements to infer viral load associations with SIL and cancer...
  15. ncbi Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants
    Sophia S Wang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5104, Rockville, MD 20854 7234, USA
    Cancer Epidemiol Biomarkers Prev 18:113-20. 2009
    ..Investigations on the molecular distinctions along the disease continuum of cervical pathogenesis by HPV type are needed...
  16. ncbi Age-related changes of the cervix influence human papillomavirus type distribution
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, Bethesda, MD 20892 7234, USA
    Cancer Res 66:1218-24. 2006
    ..These patterns need to be confirmed in other studies and populations. We suggest that these genetically distinct groups of HPV types may differ in tissue preferences, which may contribute to their differences in carcinogenic potential...
  17. ncbi Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica
    Sophia S Wang
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 13:1355-60. 2004
    ..Whereas our data support the diagnostic potential for p16INK4a, further prospective studies with detailed follow-up determining the prognostic capacity of this marker are needed...
  18. ncbi Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008
    ..These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages...
  19. ncbi A population-based study of vaginal human papillomavirus infection in hysterectomized women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 190:458-67. 2004
    ..e., A3/A4/A15) may have a predilection for vaginal epithelium...
  20. ncbi The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
    Michelle J Khan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rm. 7074, Rockville, MD 20852, USA
    J Natl Cancer Inst 97:1072-9. 2005
    ..CONCLUSIONS: HPV screening that distinguishes HPV16 and HPV18 from other oncogenic HPV types may identify women at the greatest risk of > or = CIN3 and may permit less aggressive management of other women with oncogenic HPV infections...
  21. ncbi Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:46-52. 2003
    ..We evaluated whether simultaneous screening with a Pap test and human papillomavirus (HPV) testing is useful for assessing the risk for cervical intraepithelial neoplasia (CIN) 3 or cervical cancer...
  22. ncbi Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions
    Mark E Sherman
    Department of Health and Human Services, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland 20892-7374, USA
    Cancer Epidemiol Biomarkers Prev 12:1038-44. 2003
    ..These factors severely limit the clinical use of load measurements irrespective of HPV testing methodology...
  23. ncbi Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited
    Jill Koshiol
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852 7248, USA
    Cancer Epidemiol Biomarkers Prev 18:1631-7. 2009
    ..Although genetic variation in TP53 might affect the natural history of HPV and cervical cancer, further work is needed to elucidate the possible mechanism...
  24. ncbi Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 11:1394-9. 2002
    ....
  25. ncbi A comparison of cervical and vaginal human papillomavirus
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Sex Transm Dis 34:849-55. 2007
    ..Previous studies have failed to present data on or detect a broad spectrum of HPV genotypes and/or have not carefully sampled the vagina, instead relying on self-collection that is likely contaminated with cervical cells...
  26. ncbi CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples
    Joseph D Carreon
    Division of Cancer Epidemiology and Genetics, The National Cancer Institute, National Institutes of Health, Department of Health and Human Services Rockville, Maryland 20852, USA
    Int J Gynecol Pathol 26:441-6. 2007
    ..The CIN3 is a substantially more reproducible diagnosis that can be validated more frequently with HPV tests and cytological interpretations than CIN2...
  27. ncbi Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Obstet Gynecol 109:1325-31. 2007
    ....
  28. ncbi A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 191:1808-16. 2005
    ..In some populations, HPV prevalence demonstrates a second peak in older women. Longitudinal data may help to explain this second peak...
  29. ncbi Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer
    Sophia S Wang
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rm 5104, Rockville, MD 20852 7234, USA
    J Infect Dis 199:20-30. 2009
    ..We examined host genetic factors to identify those more common in individuals whose human papillomavirus (HPV) infections were most likely to persist and progress to cervical intraepithelial neoplasia grade 3 (CIN3) and cancer...
  30. ncbi Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20854 7234, USA
    Int J Cancer 124:964-9. 2009
    ..We are now using these sharpened diagnostic categories to search for novel biomarkers predicting the risk of progression and invasion...
  31. ncbi Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality
    Melinda Butsch Kovacic
    Division of Cancer Epidemiology and Genetics and Cancer Prevention Fellowship Program, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 66:10112-9. 2006
    ..The lack of evident severe abnormalities associated with HPV18 and related HPV types might have implications for screening for poorly detected glandular and alpha7-related lesions...
  32. ncbi Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    BMJ 339:b2569. 2009
    ....
  33. ncbi A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women
    Philip E Castle
    National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD 20892, USA
    J Natl Cancer Inst 94:1406-14. 2002
    ..However, these potential risk factors have not been adequately studied in prospective studies...
  34. ncbi The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Rockville, Maryland 20859, USA
    Sex Transm Dis 34:494-502. 2007
    ..We wanted to explore early HPV natural history and CIN 3 prospectively...
  35. ncbi Accuracy of cervical specimens obtained for biomarker studies in women with CIN3
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5014, Rockville, MD 20854 7234, USA
    Gynecol Oncol 115:493-6. 2009
    ..We developed a protocol to collect representative cervical specimens based on colposcopic evaluation from women treated with loop electrosurgical excision procedure (LEEP)...
  36. ncbi Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Int J Cancer 125:1649-56. 2009
    ....
  37. ncbi A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study
    Patti E Gravitt
    Department of Epidemiology and Molecular Microbiology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 17:1248-54. 2008
    ..We were interested in comparing the performance of Linear Array (LA; Roche Molecular Systems) to Hybrid Capture 2 (hc2; Digene) for the detection of carcinogenic human papillomavirus (HPV) and cervical precancer...
  38. ncbi Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 203:814-22. 2011
    ..Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking...
  39. ncbi Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 20:946-53. 2011
    ..Here, we present the HPV genotypes found in first ?500 cases of cervical intraepithelial neoplasia grade 3 (CIN3) or more severe disease (CIN3+) diagnosed at the study baseline...
  40. ncbi Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease
    Anil K Chaturvedi
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072 Rockville, MD 20852, USA
    J Infect Dis 203:910-20. 2011
    ..We investigated coinfection patterns for 25 human papillomavirus (HPV) types and assessed the risk conferred by multiple HPV types toward cervical disease...
  41. ncbi Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies
    Sophia S Wang
    Interdisciplinary Studies Section, Division of Cancer Epidemiology and Genetics, Environmental Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892 7234, USA
    J Infect Dis 186:598-605. 2002
    ..Given the relationship between HLA-C and its receptors on natural killer (NK) cells, a role is proposed for NK function in human papillomavirus infection and cervical neoplasia...
  42. ncbi Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 12:1449-56. 2003
    ....
  43. ncbi Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting
    Sarah Coseo Markt
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    J Infect Dis 205:498-505. 2012
    ..The aim of this analysis was to assess the longitudinal relationship of abnormal cytology and HPV positivity in a 7-year prospective study of 2500 women in Guanacaste, Costa Rica...
  44. ncbi Human papillomavirus prevalence in women who have and have not undergone hysterectomies
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA
    J Infect Dis 194:1702-5. 2006
    ..5% for WH) between the 2 groups of women. Although WH have a similar prevalence of carcinogenic HPV infection, compared with WNH without a cervix, they have minimal risk of HPV-induced cancer and are unlikely to benefit from HPV testing...
  45. ncbi Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852 7234, USA
    Cancer Res 70:8578-86. 2010
    ..Our novel approach to study multiple genotype infections in cervical disease with the use of unsupervised hierarchical clustering can address complex genotype distributions on a population level...
  46. ncbi A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study
    Mark Schiffman
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 20:1398-409. 2011
    ..Adding HPV testing to cytology is recommended for women ?30 but long-term prospective studies of HPV testing are rare...
  47. ncbi Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
    Aimee R Kreimer
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 12:862-70. 2011
    ..Human papillomavirus (HPV) 16 and 18 infections cause most cases of anal cancer. We assessed efficacy of an AS04-adjuvanted HPV 16 and HPV 18 vaccine against anal infection with HPV 16, HPV 18, or both (HPV 16/18)...
  48. ncbi Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology
    Kathleen McIntyre-Seltman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892-7234, USA
    Cancer Epidemiol Biomarkers Prev 14:1165-70. 2005
    ..Smoking cessation trials targeting this population might be warranted...
  49. ncbi Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Microbiol 41:4022-30. 2003
    ..68 to 0.79). In conclusion, we suggest that HC3 (>/=0.6 RLU/PC) may be slightly more sensitive than and equally specific test as HC2 (>/=1.0 RLU/PC) for the detection of CIN3+ over the duration of typical screening intervals...
  50. ncbi Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
    Cancer 95:2145-51. 2002
    ..The absolute risk of a subsequent abnormal Pap test for these women is uncertain. Therefore, the proper counseling and clinical management of these women is also uncertain...
  51. ncbi Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
    ..We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18...
  52. ncbi Comparative performance of human papillomavirus DNA testing using novel sample collection methods
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, MSC 7231, Rockville, MD 20852, USA
    J Clin Microbiol 49:4185-9. 2011
    ..HC2 is likely more clinically specific, although possibly less sensitive, than either PCR test. Thus, use of HC2 on cervicovaginal specimens for screening could result in fewer referrals compared to LA and Amplicor...
  53. ncbi Comparisons of HPV DNA detection by MY09/11 PCR methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Virol 68:417-23. 2002
    ..Our data also suggest that studies reporting HPV DNA detection by PCR need to report the type of polymerase used, as well as other assay specifics, and underscore the need for worldwide standards of testing...
  54. ncbi Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20882, USA
    Lancet Oncol 12:663-72. 2011
    ....
  55. ncbi Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Low Genit Tract Dis 12:1-7. 2008
    ....
  56. ncbi Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Aimee R Kreimer
    National Cancer Institute, NIH, 6130 Executive Boulevard, Bethesda, MD 20892 7333, USA
    Cancer Epidemiol Biomarkers Prev 15:908-14. 2006
    ....
  57. ncbi Comparison of two PCR-based human papillomavirus genotyping methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234
    J Clin Microbiol 46:3437-45. 2008
    ..Both approaches are suitable for monitoring the impact of HPV16/18 vaccines in clinical trials...
  58. ncbi Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
    J Natl Cancer Inst 102:1653-62. 2010
    ..Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown...
  59. ncbi Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine
    Aimee R Kreimer
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7084, Rockville, MD 20852, USA
    J Natl Cancer Inst 103:1444-51. 2011
    ..Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest...
  60. ncbi Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:1066-71. 2005
    ....
  61. ncbi Effect of the number of biopsies on the subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 114:1057-62. 2009
    ..To analyze the effect of number of biopsies taken at enrollment with incident human papillomavirus (HPV) infections detected at the next 6-month visit...
  62. ncbi Interlaboratory reliability of Hybrid Capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Am J Clin Pathol 122:238-45. 2004
    ..73); among those with equivocal or abnormal cytologic findings, kappa values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA...
  63. ncbi PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:256-60. 2005
    ..3% (95% CI, 74.7-91.4%), respectively. We conclude that pooling specimens and testing by PCR may be useful for discriminating HPV DNA-positive from completely negative specimen sets in women who are likely to have been HPV DNA-negative.>..
  64. ncbi Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 199:1612-20. 2009
    ..The impact of loop electrosurgical excision procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new human papillomavirus (HPV) infections is not well described...
  65. ncbi Correlates of IL-10 and IL-12 concentrations in cervical secretions
    Patti E Gravitt
    Interdisciplinary Studies Section, Environmental Epidemiology Branch, DCEG, National Cancer Institute, 6120 Executive Blvd, EPS 7059, Bethesda, Maryland 20852, USA
    J Clin Immunol 23:175-83. 2003
    ..Future analyses of cervical cytokine levels and HPV infection should control for the inherent variation of local cytokine levels due to hormonal influences, hemoglobin contamination, pH, and cervical secretion volume differences...
  66. ncbi The promise of global cervical-cancer prevention
    Mark Schiffman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 353:2101-4. 2005
  67. ncbi A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7234, USA
    Am J Clin Pathol 124:722-32. 2005
    ..Smaller amounts of material used in PCR could have limited its sensitivity, but our results demonstrate the importance of optimization and standardization of PCR-based assays for clinical applications...
  68. ncbi Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci
    Mary Carrington
    Basic Research Program, Laboratory of Genomic Diversity, Science Applications International Corporation Frederick, Inc, National Cancer Institute, Frederick, MD 21702, USA
    J Exp Med 201:1069-75. 2005
    ....
  69. ncbi Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Sex Transm Dis 29:182-7. 2002
    ..Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity...
  70. ncbi The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology
    Mark E Sherman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7374, USA
    Cancer 111:15-25. 2007
    ..The Bethesda System (TBS) along with its companion atlas was updated in 2001 to improve standardization, clarity, and reproducibility of cervical cytology reporting...
  71. ncbi Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Obstet Gynecol 197:356.e1-6. 2007
    ....
  72. ncbi Interobserver agreement in the evaluation of digitized cervical images
    Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852, USA
    Obstet Gynecol 110:833-40. 2007
    ..To estimate the agreement among multiple expert colposcopists evaluating high-resolution digitized cervigrams taken from patients with a variety of human papillomavirus (HPV) infection states and previous cervigram interpretations...
  73. ncbi Preparing digitized cervigrams for colposcopy research and education: determination of optimal resolution and compression parameters
    Jose Jeronimo
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics DCEG, National Cancer Institute, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 10:39-44. 2006
    ..The National Cancer Institute and National Library of Medicine are involved in a large effort to improve colposcopic assessment and, in preparation, are conducting methodologic research...
  74. ncbi Human papillomavirus genotype specificity of hybrid capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5030, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:2595-604. 2008
    ..In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported...
  75. ncbi Detection of precancerous cervical lesions is differential by human papillomavirus type
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 69:3262-6. 2009
    ..001). These results indicate the underrepresentation of HPV18/45 in precancers, whereas HPV16-associated CIN3+ is diagnosed much earlier. Whether the underrepresentation of 18/45 may be due to occult pathology needs further investigation...
  76. ncbi Digital tools for collecting data from cervigrams for research and training in colposcopy
    Jose Jeronimo
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics DCEG, National Cancer Institute, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 10:16-25. 2006
    ..In this article, we describe the perceived need for the resource and its components...
  77. ncbi Does the interval between papanicolaou tests influence the quality of cytology?
    Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20892, USA
    Cancer 105:133-8. 2005
    ..It is commonly believed that the sensitivity of Papanicolaou (Pap) tests decreases with a short interval between cytology samplings. To the authors' knowledge, there is only limited evidence to support this belief...
  78. ncbi Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5012, Rockville, MD 20854 7234, USA
    Gynecol Oncol 112:293-9. 2009
    ..We wanted to identify the most promising methylation marker candidates for cervical cancer early detection...
  79. ncbi Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Int J Cancer 117:1007-12. 2005
    ....
  80. ncbi Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
    J Clin Microbiol 40:1088-90. 2002
    ..68 and the linear-weighted kappa was 0.76. The results of this study indicate that HC 2 testing is reproducible even among cytologically normal women with low test values...
  81. ncbi A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study
    Nicolas Wentzensen
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 204:94-102. 2011
    ..A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18...
  82. ncbi The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 127:805-15. 2007
    ....
  83. ncbi Medication use, medical conditions, and the risk of human papillomavirus infection and subsequent cervical intraepithelial neoplasia 3 among women with mild cytologic abnormalities
    Sophia S Wang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, MD 20852-7234, USA
    Cancer Epidemiol Biomarkers Prev 14:542-5. 2005
  84. ncbi Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage
    Sophia S Wang
    Interdisciplinary Studies Section, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 11:419-20. 2002
  85. ncbi ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, Maryland, USA
    Obstet Gynecol 99:671-4. 2002
  86. ncbi Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Clin Diagn Lab Immunol 11:399-405. 2004
    ..These findings require confirmation...
  87. ncbi Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3
    Aimee R Kreimer
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:11-6. 2007
    ..Data from Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study were used to evaluate HPV persistence and reappearance after LEEP...
  88. ncbi Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type
    Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Obstet Gynecol 197:47.e1-8. 2007
    ..Infection with carcinogenic human papillomaviruses (HPVs) is necessary for cervical precancer and cancer, but the effects of type-specific HPV infection on cervical appearance are poorly understood...
  89. ncbi Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5004, MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 19:1675-81. 2010
    ..There are few large case series describing the human papillomavirus (HPV) genotypes found in women diagnosed with rigorously reviewed cervical intraepithelial neoplasia grade 3 (CIN3), cervical precancer...
  90. ncbi Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 110:288-95. 2007
    ....
  91. ncbi Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
    Sholom Wacholder
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rockville, MD 20852, USA
    BMJ 340:c712. 2010
    ..To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage...
  92. ncbi An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)
    Philip E Castle
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 111:847-56. 2008
    ....
  93. ncbi Variable risk of cervical precancer and cancer after a human papillomavirus-positive test
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Obstet Gynecol 117:650-6. 2011
    ..To explore the effect of screening history on the risk of cervical precancer and cancer after an human papillomavirus (HPV)-positive test...
  94. ncbi An evaluation by midwives and gynecologists of treatability of cervical lesions by cryotherapy among human papillomavirus-positive women
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    Int J Gynecol Cancer 19:728-33. 2009
    ..To estimate efficacy of a visual triage of human papillomavirus (HPV)-positive women to either immediate cryotherapy or referral if not treatable (eg, invasive cancer, large precancers)...
  95. ncbi Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2
    Philip E Castle
    Divisions of Cancer Epidemiology and Genetics, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 113:18-25. 2009
    ....
  96. ncbi Stability of archived liquid-based cervical cytologic specimens
    Philip E Castle
    The National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland 20892 7234, USA
    Cancer 99:89-96. 2003
    ..However, long-term DNA stability and cytologic stability of these biospecimens have not been evaluated...
  97. ncbi Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 7013, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 19:1668-74. 2010
    ..Compared with pooled-probe testing, measuring HPV genotype-specific persistence might better predict subsequent grade 3 cervical intraepithelial neoplasia (CIN3)...
  98. ncbi Why do Black Americans have a higher risk of pancreatic cancer than White Americans?
    Debra T Silverman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Epidemiology 14:45-54. 2003
    ..For several decades, the incidence of pancreatic cancer has been 50% to 90% higher among blacks than among whites in the United States. The purpose of this study was to identify risk factors that may contribute to this racial disparity...
  99. ncbi Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)
    Mark E Sherman
    Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7374, USA
    J Natl Cancer Inst 94:102-7. 2002
    ..Considering age or viral load could improve colposcopy triage...
  100. ncbi Treatability by cryotherapy in a screen-and-treat strategy
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA
    J Low Genit Tract Dis 13:174-81. 2009
    ..We estimated the percentage of women infected with human papillomavirus (HPV+) who cannot be immediately treated with cryotherapy...